Risk of scleroderma according to the type of immune checkpoint inhibitors
Benjamin Terrier, S. Humbert, Laure‐Hélène Préta, Laure Delage, Jérôme Razanamahery, Sara Laurent‐Roussel, R. Mestiri, Lauren Beaudeau, Paul Legendre, François Goupil, Jérôme Hadjadj, Marie‐Claude Stolzenberg, Jean‐Marc Tréluyer, Virginie Westeel, Marie‐Blanche Valnet‐Rabier, Marie Wislez, Luc Mouthon, Laurent Chouchana
Topics & Concepts
NivolumabMedicineDurvalumabPembrolizumabScleroderma (fungus)AtezolizumabIpilimumabDermatologyAdverse effectPharmacovigilanceInternal medicineEosinophilic fasciitisImmunologyOncologyCancerImmunotherapyEosinophiliaInoculationCancer Immunotherapy and BiomarkersSystemic Sclerosis and Related DiseasesInflammatory Myopathies and Dermatomyositis